|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
Middle East Pharm. & Chem. Med. Appl. (الشرق الأوسط ميد فارما)
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Middle East Pharm. & Chem. Med. Appl. (الشرق الأوسط ميد فارما) Headquarters Mobes-Albaqa 1063 Amman 11821; Amman; West Zone; 11821 |
Status: Listed Legal Form: Other non-liability limited Operational Status: Operational ISIN CODE : JO4107311014 Financial Auditors: Arab Professionals (2012) Total Employees: 288 Tel: 00962 6 4726723 |
|
Company Description |
| Middle East Pharmaceutical and Chemical Industries Company, also known as Midpharma, is a Jordan-based company engaged in manufacturing and production of pharmaceuticals, medical analysis and chemicals related to the pharmaceuticals industry. In addition, the Company operates in establishing Medical and Pharmaceutical Research Centers. The Company's main products are antibiotics, antihypertensive, anti-diabetics, anti-ulcerants, antifungal, hypolipidemics, analgesics, antipyretics, multivitamins | ||
|
||
Company Analysis |
| According to the Individual - Audited financial statement for the Year of 2011, total net operating revenues decreased with -53.39%, from JOD 12,834.331 thousands to JOD 5,982.489 thousands. The results of the period reached JOD -4,318.225 thousands at the end of the period against JOD 437.706 thousands last year. Return on equity (Net income/Total equity) went from 3.43% to -51.15%, the Return On Asset (Net income / Total Asset) went from 1.56% to -17.09% and the Net Profit Margin (Net Income/Net Sales) went from 3.41% to -72.18% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 199.23% compared to 120.42% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 1.02 to 0.77 when compared to the previous year. |
Key Executives |
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2011 Y (non-cons) |
2010 Y (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| Finglobe - MENA Spread Financial Statements | Finglobe - MENA Spread Financial Statements | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
25,260 |
28,125 |
| ||
Current Assets |
12,875 |
15,657 |
| ||
Total Liabilities |
16,818 |
15,365 |
| ||
Shareholders Equity |
8,441 |
12,759 |
| ||
Current Liabilities |
16,818 |
15,365 |
| ||
| * All the accounts are in JOD. | ||
Income Statement
| ||
Total Operating Revenue |
5,982 |
12,834 |
| ||
Net Profit (Loss) |
-4,318 |
437 |
| ||
| * All the accounts are in JOD. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
-17.09% |
1.56% |
| ||
Annualised Return on Assets (ROA) |
-17.09% |
1.56% |
| ||
Return on Equity (ROE) |
-51.15% |
3.43% |
| ||
Annualised Return on Equity (ROE) |
-33.84% |
3.42% |
| ||
Return on Sales (ROS) |
-72.18% |
3.41% |
| ||
Gross Profit Margin |
195.96% |
143.13% |
| Efficiency Ratios | ||
| ||
Inventory Turnover |
1.08x |
2.20x |
| ||
Current asset turnover |
0.46x |
0.82x |
| ||
Fixed-asset turnover |
0.48x |
1.03x |
| ||
Asset Turnover |
0.24x |
0.46x |
| Valuation figures and ratios | ||
| ||
Enterprise value |
66,350 |
64,037 |
| ||
Bookvalue (BV) |
8,441 |
12,759 |
| ||
Net Cash |
-16,114 |
-15,084 |
| Liquidity Ratios | ||
| ||
Current Ratio |
76.56% |
101.9% |
| ||
Quick ratio |
43.69% |
63.99% |
| ||
Doom's day ratio |
4.18% |
1.83% |
| Leverage Ratios | ||
| ||
Leverage ratio |
299.23% |
220.42% |
| ||
Debt to equity |
199.23% |
120.42% |
| ||
Debt to total assets |
66.58% |
54.63% |
| Market ratios | ||
| ||
Market Cap / Net cash |
-3.12 |
-3.25 |
| Trend Ratios | ||
| ||
Revenue Trend |
46.61% |
107.42% |
| ||
Net Income Trend |
-986.56% |
73.24% |
| ||
 |